DC
ARQT icon

Diametric Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Diametric Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,477
Closed -$593K – 384
2025
Q3 		$593K Sell
31,477
-7,381
-19% -$116K 0.22% 114
2025
Q2 		$545K Buy
38,858
+14,514
+60% +$203K 0.29% 98
2025
Q1 		$381K Buy
24,344
+3,974
+20% +$56K 0.45% 77
2024
Q4 		$284K Sell
20,370
-12,537
-38% -$137K 0.19% 168
2024
Q3 		$306K Buy
32,907
+20,481
+165% +$202K 0.15% 208
2024
Q2 		$116K Buy
+12,426
New +$112K 0.06% 302
2023
Q2 		– Sell
-14,644
Closed -$161K – 353
2023
Q1 		$161K Buy
+14,644
New +$212K 0.08% 240

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return